Trial Profile
A Phase 1, randomised, open-label, two-period, single dose, crossover study to evaluate the safety, tolerability and pharmacokinetics of JZP-110 in healthy subjects under fed and fasted conditions
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Feb 2019
Price :
$35
*
At a glance
- Drugs Solriamfetol (Primary)
- Indications Hypersomnia; Narcolepsy; Renal failure; Sleep apnoea syndrome
- Focus Pharmacokinetics
- 28 Dec 2018 Primary endpoint [The geometric mean ratios for Cmax and AUC0 (Fed/fasted)] has been met.
- 28 Dec 2018 Pharmacokinetics results (n=32) of Solriamfetol (JZP-110) in healthy subjects with and without food were published in the Clinical Therapeutics.
- 29 Sep 2017 New trial record